With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
TMO trades against a final fair-value range of $384.14-$618.78, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A stress test assuming flat organic growth for three years and a terminal multipleTerminal multipleThe exit P/E or EV/EBITDA we apply to the final year of an explicit forecast. Anchored to the business's long-run quality and the prevailing risk-free rate. contraction to 15x yields a downside value near $384. This scenario materializes if biopharma R&D budgets are slashed and pricing power evaporates.
Extended depression in early-stage biotech funding permanently impairs the growth trajectory of the life sciences solutions segment.
Elevated debt levels ($31B+) and higher interest rates restrict accretive acquisitions, eliminating the historical EPS compounding mechanism.
A major acquisition fails to deliver projected synergies, destroying ROIC and leading to a significant multiple de-rating.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $39.21B | $44.92B+14.6% | $42.86B-4.6% | $42.88B+0.0% | — | +2.3% |
| Gross profit | $19.64B | $18.97B | $17.10B | $17.70B | — | -2.6% |
| Operating income | $10.23B | $8.51B | $7.32B | $7.72B | — | -6.8% |
| Net income | $7.73B | $6.95B-10.1% | $6.00B-13.7% | $6.34B+5.7% | — | -4.8% |
| EPS (diluted) | — | $17.63 | $15.45 | $16.53 | $17.74 | +0.2% |
| EBITDA | $11.97B | $11.94B | $11.08B | $11.54B | — | -0.9% |
| R&D | $1.41B | $1.47B | $1.34B | $1.39B | — | -0.3% |
| SG&A | $8.01B | $8.99B | $8.45B | $8.60B | — | +1.8% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Free cash flow conversion falling persistently below 100% of net income. | Monitor | Deterioration versus the report thesis |
| Management abandoning the long-term mid-single-digit organic growth target. | Monitor | Deterioration versus the report thesis |
